Shares of Rapt Therapeutics (RAPT) have gained 43.5% over the past four weeks to close the last trading session at $26.71, but there could still be a solid upside left in the stock if short-term price ...
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you ...
Hosted on MSN
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet
Shares of Rapt Therapeutics (RAPT) have gained 0.5% over the past four weeks to close the last trading session at $11.74, but there could still be a solid upside left in the stock if short-term price ...
Shares of Rapt Therapeutics have gained 34.2% over the past four weeks to close the last trading session at $10.8, but there could still be a solid upside left in the stock if short-term price targets ...
Rapt Therapeutics (RAPT) closed the last trading session at $29.20, gaining 38.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
Investors have bought into Rapt’s plan, funnelling $150 million into the biotech. (Hwangdaesung/iStock/Getty Images Plus) Rapt Therapeutics has charted a new course ...
The last time I spoke about RAPT Therapeutics, Inc. (RAPT), it was in a Seeking Alpha article entitled "RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus." With respect to this article, I ...
Rapt Therapeutics (RAPT) closed the last trading session at $21.43, gaining 0.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results